天天中文日韩熟妇天堂,国产色精品视频91色,亚洲伊人久久在线,亚洲熟女五十路,亚洲人妻丝袜在线,亚洲综合日韩在线,亚洲欧美另类熟女精品,大量国产欧美日韩久久,日韩欧美亚洲

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application approved for small-molecule oral drug SHEN26 Capsule against COVID-19
2022-07-17

2022-07-17

On the evening of July 17, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Approval for Drug Clinical Trial issued by the National Medical Products Administration, indicating that the clinical trial of small-molecule oral drug SHEN26 Capsule against COVID-19 jointly developed by Shenzhen Kexing and Shenzhen Antiv was approved.
Kexing Biopharm's clinical trial application accepted for Human Interferon α2b Effervescent Capsule
2022-06-27

2022-06-27

On the evening of June 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration, indicating that its clinical trial application for "Human Interferon α2b Vaginal Effervescent Capsule" was accepted.
Ma Zhiyong, Secretary of CPC Zhangqiu District Committee of Jinan City, and his delegation visit Kexing Biopharm for research
2022-05-07

2022-05-07

On May 6, 2022, Ma Zhiyong, Secretary of the CPC Zhangqiu District Committee of Jinan City, Shandong Province, and his delegation visited Kexing Biopharm to research the Company's projects and enterprise operation. Cui Ning, Vice President of Kexing Biopharm and General Manager of Shandong Business Unit, was in charge of the reception.
Kexing Biopharm Signs Exclusive Promotion Service Agreement for Infliximab (Reminton?)
2022-03-31

2022-03-31

On March 31, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that the Exclusive Promotion Service Agreement for Infliximab (Reminton?) in Chinese Mainland was signed with Taizhou Mabtech, granting Kexing Biopharm the exclusive promotion right of infliximab (Reminton?) in Chinese mainland.
Kexing Biopharm Establishes Holding Company for Developing Veterinary Vaccines
2022-03-15

2022-03-15

Scientific Vaccine Innovations for Harmonious Coexistence Between Humans and Animals

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation

锡林郭勒盟| 崇仁县| 越西县| 孟村| 青阳县| 涪陵区| 黄梅县| 田东县| 梨树县| 河东区| 出国| 利津县| 景宁| 德化县| 房山区| 河南省| 岑巩县| 阿巴嘎旗| 江安县| 晋城| 江山市| 桂东县| 云阳县| 泾川县| 台中市| 隆昌县| 胶州市| 五原县| 临泽县| 开封县| 澳门| 郓城县| 财经| 浦江县| 平安县| 出国| 东丰县| 陈巴尔虎旗| 神木县| 嘉义市| 开平市|